ClinicalTrials.gov Identifier: NCT03439943.
| Study name | Study to evaluate the effect of lixisenatide in patients with Parkinson's disease (LixiPark) |
| Methods | Multi‐centre, randomised, placebo‐controlled, double‐blind, parallel‐arm proof‐of‐concept trial |
| Participants | With early PD |
| Interventions |
Intervention: lixisenatide (10 μg/d for 14 days, then 20 μg/d), once daily subcutaneously Comparator: placebo, once‐daily subcutaneous injection |
| Outcomes | Change from baseline to end point (M12) in MDS‐UPDRS III motor examination score, evaluated in the best ON condition in patients with early Parkinson's disease |
| Starting date | June 2018 |
| Contact information | olivier.rascol@univ-tlse3.fr |
| Notes |